ONCOLOGY

57% intracranial clinical benefit in phase 2 trial.

Overall, the incidence of cancer was 1.5 times higher in children who had received at least one CT scan five years previously.

The new review process will streamline FDA evaluation of other oncology drugs.

A NICE appraisal committee determined that it would be “unethical” not to offer the treatment to patients in the UK

Recombinant nonpathogenic polio-rhinovirus chimera achieves 21% 3-yr survival in patients with recurrent glioblastoma.

The regulatory agency has advised of cases of significant rebound hypercalcaemia after discontinuation in patients with giant cell tumour of bone.

WCGI 2018 - New developments in Neuroendocrine cancer (NEC) and Bile Duct Cancer (BDC) in the last 12 Months

Cytokine release syndrome causes multiple brain effects.

Available studies were very few and of low quality.

Indoximod reverses IDO induced immunosuppression to act against recurrent/refractory DIPG.

Researchers are optimistic about the therapeutic potential of mifepristone for patients with vestibular schwannomas.

No reduction in early-onset left ventricular ejection fraction.

£45 million in funding to be released over the next 5 years.

Safety study uncovers potential clinical benefit with median OS approaching 8 months.